PALBOCICLIB - Generic Drug Details

What are the generic drug sources for palbociclib and what is the scope of freedom to operate?

Palbociclib is the generic ingredient in two branded drugs marketed by Pfizer and Zydus Lifesciences, and is included in three NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound. There are nine tentative approvals for this compound.

Summary for PALBOCICLIB

International Patents:	169
US Patents:	3
Tradenames:	2
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	326
Patent Applications:	7,675
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PALBOCICLIB
What excipients (inactive ingredients) are in PALBOCICLIB?	PALBOCICLIB excipients list
DailyMed Link:	PALBOCICLIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PALBOCICLIB

Dosage:

CAPSULE;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PALBOCICLIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rovi Pharmaceuticals Laboratories	PHASE3
Stephanie Berg	PHASE2
Pfizer	PHASE2

See all PALBOCICLIB clinical trials

Generic filers with tentative approvals for PALBOCICLIB

Applicant	Application No.	Strength	Dosage Form
		100MG	CAPSULE
		125MG	CAPSULE
		100MG	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for PALBOCICLIB

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PALBOCICLIB

L01EF	Cyclin-dependent kinase (CDK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for PALBOCICLIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IBRANCE	Tablets	palbociclib	75 mg, 100 mg and 125 mg	212436	1	2020-11-24
IBRANCE	Capsules	palbociclib	75 mg, 100 mg and 125 mg	207103	12	2019-02-04

US Patents and Regulatory Information for PALBOCICLIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No					Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-002	Nov 1, 2019		RX	Yes	No

Expired US Patents for PALBOCICLIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015

EU/EMA Drug Approvals for PALBOCICLIB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Ibrance	palbociclib	EMEA/H/C/003853Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.	Authorised	no	no	no	2016-11-09

International Patents for PALBOCICLIB

Country	Patent Number	Title	Estimated Expiration
Argentina	094842
Australia	2014220354
Brazil	112015019508
Canada	2900322
China	105008357
China	107759594

Supplementary Protection Certificates for PALBOCICLIB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1470124	17C1012	France		PRODUCT NAME: PALBOCICLIB, ET TOUTES SES FORMES RELEVANT DE LA PROTECTION DU BREVET DE BASE.; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	C20170012 00212	Estonia		PRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
1470124	C 2017 016	Romania		PRODUCT NAME: PALBOCICLIB OPTIONAL SUB FORMA DE SARE, ESTER, AMIDA SAUPROMEDICAMENT AL ACESTUIA, ACCEPTABILEFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/16/1147; DATE OF NATIONAL AUTHORISATION: 20161109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1147; DATE OF FIRST AUTHORISATION IN EEA: 20161109
1470124	LUC00009	Luxembourg		PRODUCT NAME: PALBOCICLIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL , D'UN ESTER, D'UN AMIDE OU D'UN PROMEDICAMENT PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/16/1147 20161111
1470124	C01470124/01	Switzerland		PRODUCT NAME: PALBOCICLIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66138 31.01.2017
1470124	132017000046148	Italy		PRODUCT NAME: PALBOCICLIB, OPZIONALMENTE NELLA FORMA DI UN SALE, ESTERE, AMMIDE O PROFARMACO FARMACEUTICAMENTE ACCETTABILE(IBRANCE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1147/001-006, 20161111

Palbociclib Market Dynamics, Revenue Outlook, Patent Expiry, and Generic Entry Risk

Last updated: August 24, 2026

Palbociclib, marketed by Pfizer as Ibrance, remains a major CDK4/6 inhibitor franchise but has entered a mature-growth phase. Global revenue reached approximately $4.8 billion in 2023, down from its peak as competition from ribociclib and abemaciclib increased. The product retains strong metastatic breast-cancer demand, but its commercial ceiling is constrained by failure to establish a role in early breast cancer and by expected U.S. generic entry after the late-2020s patent period. [1]

The principal business risks are declining treatment share, U.S. patent challenges, international loss of exclusivity, and physician migration toward CDK4/6 inhibitors with broader early-stage or overall-survival data. Palbociclib remains commercially defensible because of its established safety profile, extensive clinical experience, global regulatory approvals, and entrenched use in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

What is palbociclib and how does Ibrance work?

Palbociclib is an orally administered, selective cyclin-dependent kinase 4 and 6 inhibitor. It blocks retinoblastoma-protein phosphorylation, causing cell-cycle arrest in the G1 phase. The drug is administered on a 21-days-on, 7-days-off schedule and is used with endocrine therapy.

The FDA-approved indication is HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:

• An aromatase inhibitor as initial endocrine-based therapy for postmenopausal women and men.
• Fulvestrant for patients with disease progression after endocrine therapy.
• A luteinizing hormone-releasing hormone agonist in premenopausal women and men when clinically appropriate. [2]

The approved strength is 125 mg, with dose reductions to 100 mg and 75 mg to manage neutropenia and other toxicities.

What clinical evidence supports palbociclib?

The PALOMA clinical program established palbociclib as a standard CDK4/6 therapy in metastatic disease.

Trial	Population	Main result
PALOMA-1	Advanced HR-positive, HER2-negative breast cancer	Demonstrated early progression-free-survival benefit
PALOMA-2	First-line metastatic disease with letrozole	Progression-free survival improved versus letrozole alone
PALOMA-3	Endocrine-resistant metastatic disease	Progression-free survival improved with fulvestrant
PALOMA-4	Asian postmenopausal patients	Supported use with letrozole
PALLAS	Early-stage adjuvant breast cancer	Did not improve invasive disease-free survival
PENELOPE-B	Residual high-risk early breast cancer after neoadjuvant chemotherapy	Did not improve invasive disease-free survival

The negative PALLAS and PENELOPE-B results are commercially important. They prevented Pfizer from expanding Ibrance into the large adjuvant breast-cancer market, where abemaciclib and, more recently, ribociclib obtained more favorable positioning. [3,4]

How large is the palbociclib market?

Palbociclib is one of the largest targeted breast-cancer products by historical sales. Pfizer reported Ibrance revenue of approximately $4.8 billion in 2023, compared with approximately $5.1 billion in 2022 and more than $5 billion in earlier peak years. [1]

What drives palbociclib revenue?

The main revenue drivers are:

1. The size of the HR-positive, HER2-negative metastatic breast-cancer population.
2. Continued first-line use with aromatase inhibitors.
3. Long treatment duration for patients who maintain disease control.
4. Global access across the United States, Europe, Japan, and other major markets.
5. Established oncologist familiarity and a substantial evidence base.

The principal offset is competitive substitution. CDK4/6 inhibitors are increasingly selected based on overall-survival data, central nervous system activity, adjuvant indications, dosing convenience, and payer positioning.

How does Ibrance revenue compare with competing CDK4/6 inhibitors?

Product	Company	Main commercial position	Competitive effect on palbociclib
Ibrance, palbociclib	Pfizer	Established metastatic HR-positive, HER2-negative therapy	Baseline market leader with mature revenue
Kisqali, ribociclib	Novartis	Metastatic therapy and FDA-approved adjuvant therapy for selected early breast cancer	Strongest expansion threat
Verzenio, abemaciclib	Eli Lilly	Metastatic and high-risk early breast cancer	Benefits from adjuvant positioning and continuous dosing

Ribociclib gained commercial momentum after the NATALEE study supported adjuvant use and the FDA approved Kisqali with an aromatase inhibitor for certain early-stage HR-positive, HER2-negative breast-cancer patients in 2024. Abemaciclib has an established adjuvant indication based on monarchE. [5,6]

Palbociclib’s lack of an adjuvant indication is the central strategic disadvantage within the class.

When does palbociclib lose exclusivity?

Palbociclib does not have a single global loss-of-exclusivity date. Patent protection varies by jurisdiction, patent family, pediatric extensions, regulatory exclusivity, and litigation settlements.

In the United States, the Orange Book lists Pfizer patents covering Ibrance and palbociclib-related intellectual property. The relevant protection extends beyond the original compound and includes formulation, crystalline-form, and method-of-use claims. The commercially important U.S. generic-entry window is expected to fall in the late 2020s, subject to patent litigation outcomes and settlement terms. [7]

What patents protect Ibrance?

The U.S. patent estate has historically included claims directed to:

• Palbociclib and related 2-aminopyridine compounds.
• Pharmaceutical compositions containing palbociclib.
• Crystalline or solid-state forms.
• Methods of treating HR-positive breast cancer.
• Combination treatment with endocrine therapies.
• Dosing regimens and formulation characteristics.

Representative Ibrance-related U.S. patent litigation has involved patents including US 8,415,355 and US 8,445,432, together with later-issued patents directed to formulations, solid forms, and treatment methods. The controlling list is the FDA Orange Book entry for Ibrance, which can change as patents issue, expire, are delisted, or are affected by litigation. [7,8]

What is the Orange Book status of Ibrance?

Ibrance is an FDA-approved small-molecule drug listed in the Orange Book. It is not a biologic and does not receive biosimilar protection. Generic applicants must file abbreviated new drug applications and address listed patents through Paragraph IV certifications or other certification pathways. [7]

The practical protection profile is therefore different from a biologic franchise:

Issue	Palbociclib
Regulatory pathway for competitors	ANDA
Biosimilar exposure	Not applicable
Patent challenge mechanism	Paragraph IV or other ANDA certification
Reference product	Ibrance
Main risk after patent expiry	Multiple generic entrants and rapid price erosion

Which companies are challenging palbociclib patents?

Generic-drug companies have pursued Ibrance through Paragraph IV patent challenges and related ANDA litigation. Publicly reported proceedings have involved companies including Teva, Sun Pharmaceutical, Dr. Reddy’s Laboratories, Hetero, Zydus, Cipla, and MSN Laboratories. The defendant group can change as cases are consolidated, dismissed, settled, or resolved.

The commercial significance of these challenges is greater than the number of defendants suggests. Palbociclib is a high-value oral oncology product with established demand, making it attractive to multiple generic manufacturers. A successful challenge by one applicant could create an earlier launch opportunity, while settlements may establish staggered entry dates.

What generic launch scenarios exist for palbociclib?

Scenario	Likely market effect
Patent protection survives through the expected late-2020s period	Pfizer retains substantial U.S. revenue until authorized or independent generic entry
One generic launches after litigation victory	Rapid price discounts and payer substitution begin
Multiple generics launch simultaneously	Faster net-price erosion and larger volume transfer
Authorized generic launches first	Pfizer may preserve part of the franchise economics while controlling channel pricing
Settlement permits limited early entry	Revenue decline begins before full patent expiry but may be gradual

For a high-value oral oncology product, generic entry can reduce branded net revenue sharply within the first several quarters. The magnitude depends on the number of entrants, payer mandates, specialty-pharmacy contracts, and whether Pfizer introduces an authorized generic.

What is the FDA regulatory status of palbociclib?

The FDA granted accelerated approval to Ibrance in February 2015 for postmenopausal women with HR-positive, HER2-negative advanced breast cancer in combination with letrozole. The FDA expanded the indication in 2016 to include fulvestrant and premenopausal or perimenopausal women receiving ovarian suppression. In 2017, the FDA converted the initial accelerated approval to regular approval after confirmatory data supported clinical benefit. [2]

Palbociclib’s regulatory profile is stable. No major new indication has materially expanded its addressable market since the metastatic breast-cancer approvals.

Does palbociclib have biosimilar risk?

No. Palbociclib is a chemically synthesized small molecule, so competitors will enter through the generic-drug pathway rather than the biosimilar pathway. The relevant risks are ANDA filings, Paragraph IV litigation, patent settlements, manufacturing scale-up, and formulary substitution.

How strong is the palbociclib patent estate?

The estate is commercially meaningful but not impenetrable.

Strengths

• Multiple patent categories extend beyond the basic active ingredient.
• Ibrance has a large and durable commercial market.
• Pfizer can use litigation, settlement, authorized-generic strategy, and contracting to manage the transition.
• Treatment-method and formulation patents may complicate immediate full-market substitution.

Weaknesses

• Palbociclib is a small molecule with a conventional generic pathway.
• Core composition patents are closer to expiration than they were during the product’s growth phase.
• Method-of-use claims can be narrower and more vulnerable to validity or noninfringement arguments.
• Generic manufacturers have strong incentives to challenge high-value oncology products.
• The drug’s clinical differentiation has weakened relative to ribociclib and abemaciclib.

The patent estate should be assessed as a delaying and segmentation tool rather than a permanent barrier to generic competition.

What patent litigation affects Ibrance?

Ibrance litigation has centered on ANDA applicants seeking approval for generic palbociclib capsules and tablets. Pfizer’s claims have included composition, formulation, solid-state, and treatment patents. Outcomes may include:

• District-court judgments on validity and infringement.
• Settlements with agreed launch dates.
• Covenants not to sue on selected claims.
• Dismissal of claims after patent expiration or regulatory developments.
• Administrative patent proceedings affecting claim scope.

The most important commercial question is not whether Pfizer has several listed patents. It is whether at least one enforceable patent blocks commercial launch by a generic applicant through the relevant period.

What manufacturing and intellectual-property barriers affect palbociclib?

Palbociclib manufacturing is less technically restrictive than biologic manufacturing, but generic competitors still face development barriers.

Key barriers include:

• Demonstrating bioequivalence for the applicable dosage form.
• Controlling solid-state properties and polymorphism.
• Reproducing dissolution and stability characteristics.
• Establishing reliable active-pharmaceutical-ingredient supply.
• Meeting oncology-product quality and serialization requirements.
• Managing multiple strengths and dose-reduction presentations.
• Navigating patent claims covering formulation or crystal form.

These barriers can delay entry but are unlikely to prevent eventual multi-source competition once core legal protection weakens.

What licensing deals support palbociclib?

Palbociclib originated from Pfizer’s internal small-molecule oncology research and is not primarily a partnered asset. Pfizer’s major commercial advantage comes from internal development, global registration, manufacturing, and distribution rather than a prominent current co-commercialization agreement.

The relevant corporate transaction was Pfizer’s acquisition of Warner-Lambert in 2000, which brought Agouron Pharmaceuticals and its oncology research capabilities into Pfizer. Palbociclib was later developed within Pfizer’s oncology organization. [9]

What is the long-term financial trajectory for palbociclib?

Palbociclib is likely to follow a mature-franchise decline pattern:

1. Revenue erosion from class competition before U.S. generic entry.
2. Greater pressure in markets where ribociclib and abemaciclib have broader labels.
3. Accelerated decline after the first U.S. generic launch.
4. Steeper erosion when several ANDA holders enter.
5. Residual branded revenue from physician loyalty, international markets, and patients stabilized on existing therapy.

The product’s revenue base remains large enough to affect Pfizer’s oncology performance, but it is unlikely to return to sustained growth without a major new indication or differentiated combination strategy. The more probable outcome is managed decline with partial preservation through contracting, lifecycle management, and potential authorized-generic economics.

Key Takeaways

• Ibrance generated approximately $4.8 billion in global revenue in 2023.
• Palbociclib remains a leading metastatic breast-cancer therapy but has lost relative strategic position within the CDK4/6 class.
• Ribociclib and abemaciclib have stronger early-breast-cancer positioning.
• Failed adjuvant trials limited palbociclib’s market expansion.
• Ibrance is an FDA-approved small molecule subject to ANDA and Paragraph IV competition, not biosimilar competition.
• U.S. generic entry is a late-2020s risk, subject to Orange Book patents and litigation settlements.
• Pfizer’s patent estate is diversified across compound, formulation, solid-form, and method-of-use claims but will not permanently prevent generic competition.
• Revenue is likely to decline before and accelerate after full generic entry.

FAQs About Palbociclib Commercial and Patent Risk

What is the main competitive threat to Ibrance?

The main threat is not a single generic entrant today. It is the combined effect of ribociclib and abemaciclib gaining earlier-stage breast-cancer use while palbociclib remains concentrated in metastatic disease.

Can a generic manufacturer launch palbociclib before the listed patent expiry date?

Yes, if it prevails in Paragraph IV litigation, reaches a settlement permitting earlier entry, or relies on a certification that avoids infringement of relevant listed patents.

Does palbociclib have an advantage over ribociclib in safety?

Palbociclib has extensive clinical experience and predictable neutropenia management. Comparative selection depends on the specific patient, treatment setting, monitoring requirements, label, and physician judgment.

What happens to Ibrance pricing after generic entry?

Net pricing normally falls as payers favor generic substitution. The speed of erosion depends on the number of entrants and whether Pfizer launches an authorized generic.

Is palbociclib still commercially important after patent expiry?

Yes. A large installed patient base and established treatment guidelines can preserve substantial unit demand, although branded revenue generally contracts rapidly once multiple generics obtain market access.

References

1. Pfizer Inc. (2024). 2023 annual report. Pfizer Investor Relations.
2. U.S. Food and Drug Administration. (2024). Ibrance (palbociclib) prescribing information.
3. Turner, N. C., et al. (2018). Palbociclib in hormone-receptor-positive advanced breast cancer. New England Journal of Medicine, 379(20), 1926-1936.
4. Johnston, S., et al. (2021). Palbociclib plus endocrine therapy in early breast cancer: PALLAS and PENELOPE-B results. Journal of Clinical Oncology.
5. Novartis Pharmaceuticals. (2024). Kisqali prescribing information and FDA approval announcement.
6. Eli Lilly and Company. (2023). Verzenio prescribing information.
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
8. U.S. Patent and Trademark Office. (2024). Patent Center and patent litigation records for palbociclib-related patents.
9. Pfizer Inc. (2000). Pfizer completes acquisition of Warner-Lambert. Pfizer corporate archives.